Covid-19 y diabetes mellitus tipo 2: implicaciones en las células beta pancreáticas
DOI:
https://doi.org/10.5281/zenodo.10712093Palabras clave:
Diabetes Mellitus Tipo 2, Células Secretoras de Insulina, COVID-19, SARS-CoV-2Resumen
México presenta una alta prevalencia de enfermedades crónico-metabólicas, destacando de entre estas la diabetes mellitus tipo 2 (DMT2). Es esencial profundizar en la asociación entre la covid-19 y la DMT2, dado que ambas enfermedades tienen efectos bidireccionales. La diabetes puede incrementar la patogenicidad del virus SARS-CoV-2, debido a las alteraciones metabólicas que subyacen a esta enfermedad, lo que resulta en un aumento de la susceptibilidad y la severidad de la covid-19 entre los pacientes diabéticos, siendo una población de alto riesgo de mortalidad. Por otra parte, la infección por SARS-CoV-2 puede predisponer a los individuos a hiperglucemia o diabetes de nueva aparición. Con el propósito de comprender la asociación que existe entre la covid-19 y la DMT2, en esta revisión se enfatiza el tropismo del virus SARS-CoV-2 por las células beta pancreáticas secretoras de insulina, así como el efecto que tiene el virus sobre la fisiología de estas células.
Descargas
Referencias
Tabacof L, Tosto-Mancuso J, Wood J, et al. Post-acute COVID-19 Syndrome Negatively Impacts Physical Function, Cognitive Function, Health-Related Quality of Life, and Participation. Am J Phys Med Rehabil. 2022;101(1):48-52. doi: 10.1097/PHM.0000000000001910.
Li J, He X, Yuan Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control. 2021;49(1):82-9. doi: 10.1016/j.ajic.2020.06.008.
Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813-22. doi: 10.1016/S2213-8587(20)30272-2.
Steenblock C, Hassanein M, Khan EG, et al. Diabetes and COVID-19: Short- and Long-Term Consequences. Horm Metab Res. 2022;54(8):503-9. doi: 10.1055/a-1878-9566.
Denova-Gutierrez E, Lopez-Gatell H, Alomia-Zegarra JL, et al. The Association of Obesity, Type 2 Diabetes, and Hypertension with Severe Coronavirus Disease 2019 on Admission Among Mexican Patients. Obesity (Silver Spring). 2020;28(10):1826-32. doi: 10.1002/oby.22946.
Jedrzejak AP, Urbaniak EK, Wasko JA, et al. Diabetes and SARS-CoV-2-Is There a Mutual Connection? Front Cell Dev Biol. 2022;10:913305. doi: 10.3389/fcell.2022.913305.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80. doi: 10.1016/j.cell.2020.02.052.
V'Kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155-70. doi: 10.1038/s41579-020-00468-6.
Mu J, Fang Y, Yang Q, et al. SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2. Cell Discov. 2020;6:65. doi: 10.1038/s41421-020-00208-3.
Memon B, Abdelalim EM. ACE2 function in the pancreatic islet: Implications for relationship between SARS-CoV-2 and diabetes. Acta Physiol (Oxf). 2021;233(4):e13733. doi: 10.1111/apha.13733.
Fignani D, Licata G, Brusco N, et al. SARS-CoV-2 Receptor Angiotensin I-Converting Enzyme Type 2 (ACE2) Is Expressed in Human Pancreatic beta-Cells and in the Human Pancreas Microvasculature. Front Endocrinol (Lausanne). 2020;11:596898. doi: 10.3389/fendo.2020.596898.
Liu F, Long X, Zhang B, et al. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020;18(9):2128-30. doi: 10.1016/j.cgh.2020.04.040.
Coate KC, Cha J, Shrestha S, et al. SARS-CoV-2 Cell Entry Factors ACE2 and TMPRSS2 Are Expressed in the Microvasculature and Ducts of Human Pancreas but Are Not Enriched in beta Cells. Cell Metab. 2020;32(6):1028-40. doi: 10.1016/j.cmet.2020.11.006.
Hikmet F, Mear L, Edvinsson A, et al. The protein expression profile of ACE2 in human tissues. Mol Syst Biol. 2020;16(7):e9610. doi: 10.15252/msb.20209610.
Geravandi S, Mahmoudi-Aznaveh A, Azizi Z, et al. SARS-CoV-2 and pancreas: a potential pathological interaction? Trends Endocrinol Metab. 2021;32(11):842-5. doi: 10.1016/j.tem.2021.07.004.
Wu CT, Lidsky PV, Xiao Y, et al. SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment. Cell Metab. 2021;33(8):1565-76 e5. doi: 10.1016/j.cmet.2021.05.013.
Hayden MR. An Immediate and Long-Term Complication of COVID-19 May Be Type 2 Diabetes Mellitus: The Central Role of beta-Cell Dysfunction, Apoptosis and Exploration of Possible Mechanisms. Cells. 2020;9(11). doi: 10.3390/cells9112475.
Hernandez-Ochoa B, Ortega-Cuellar D, Gonzalez-Valdez A, et al. COVID-19 in G6PD-deficient Patients, Oxidative Stress, and Neuropathology. Curr Top Med Chem. 2022;22(16):1307-25. doi: 10.2174/1568026622666220516111122.
Olagnier D, Farahani E, Thyrsted J, et al. SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat Commun. 2020;11(1):4938. doi: 10.1038/s41467-020-18764-3.
Geca T, Wojtowicz K, Guzik P, et al. Increased Risk of COVID-19 in Patients with Diabetes Mellitus-Current Challenges in Pathophysiology, Treatment and Prevention. Int J Environ Res Public Health. 2022;19(11). doi: 10.3390/ijerph19116555.
Ramasamy S, Subbian S. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis. Clin Microbiol Rev. 2021;34(3). doi: 10.1128/CMR.00299-20.
Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. doi: 10.1172/JCI137244.
Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. doi: 10.1016/S2213-2600(20)30076-X.
Tan M, Liu Y, Zhou R, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160(3):261-8. doi: 10.1111/imm.13223.
Shao S, Yang Q, Pan R, et al. Interaction of Severe Acute Respiratory Syndrome Coronavirus 2 and Diabetes. Front Endocrinol (Lausanne). 2021;12:731974. doi: 10.3389/fendo.2021.731974.
Sen S, Chakraborty R, Kalita P, et al. Diabetes mellitus and COVID-19: Understanding the association in light of current evidence. World J Clin Cases. 2021;9(28):8327-39. doi: 10.12998/wjcc.v9.i28.8327.
Yang L, Han Y, Nilsson-Payant BE, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27(1):125-36 e7. doi: 10.1016/j.stem.2020.06.015.
Muller JA, Gross R, Conzelmann C, et al. SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab. 2021;3(2):149-65. doi: 10.1038/s42255-021-00347-1.
Tang X, Uhl S, Zhang T, et al. SARS-CoV-2 infection induces beta cell transdifferentiation. Cell Metab. 2021;33(8):1577-91 e7. doi: 10.1016/j.cmet.2021.05.015.
Kim SH, Arora I, Hsia DS, et al. New-Onset Diabetes after COVID-19. J Clin Endocrinol Metab. 2023. doi: 10.1210/clinem/dgad284.
Montefusco L, Ben Nasr M, D'Addio F, et al. Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection. Nat Metab. 2021;3(6):774-85. doi: 10.1038/s42255-021-00407-6.
Pal R, Banerjee M, Yadav U, et al. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: A systematic review of literature. Diabetes Metab Syndr. 2020;14(6):1563-9. doi: 10.1016/j.dsx.2020.08.015.
Zhu Z, Mao Y, Chen G. Predictive value of HbA1c for in-hospital adverse prognosis in COVID-19: A systematic review and meta-analysis. Prim Care Diabetes. 2021;15(6):910-7. doi: 10.1016/j.pcd.2021.07.013.
Zhu L, She ZG, Cheng X, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;31(6):1068-77 e3. doi: 10.1016/j.cmet.2020.04.021.
Gangadharan C, Ahluwalia R, Sigamani A. Diabetes and COVID-19: Role of insulin resistance as a risk factor for COVID-19 severity. World J Diabetes. 2021;12(9):1550-62. doi: 10.4239/wjd.v12.i9.1550.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2024 Revista Médica del Instituto Mexicano del Seguro Social

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores conservan sus derechos de autor y otorgan a la Revista Médica del IMSS el derecho de primera publicación. Los artículos se distribuyen bajo una Licencia Creative Commons Atribución-NoComercial-SinDerivar 4.0 Internacional, que permite su difusión siempre que se reconozca al autor y la fuente original.